July 1st 2020, 3:39pm
The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.
June 16th 2020, 7:45pm
"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.
June 12th 2020, 5:00pm
At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.
May 29th 2020, 5:00pm
The immunotherapy Bavencio improves survival when given as a maintenance treatment in patients whose advanced urothelial carcinoma did not progress on platinum-based chemotherapy.
May 19th 2020, 5:00pm
Even amid stay at home orders to mitigate the spread of the coronavirus, listen to your body and speak to your healthcare professionals when you are worried about a potential for cancer.
May 16th 2020, 6:00pm
COVID-19 has drastically changed the landscape for patients with bladder cancer, but the new challenges are not insurmountable. CURE had the chance to interview the co-founder of the Bladder Cancer Advocacy Network to discuss these changes.
May 14th 2020, 10:00pm
Amid the COVID-19 pandemic, the Bladder Cancer Advocacy Network is honoring Bladder Cancer Awareness Month in a slightly different way from previous years.
April 22nd 2020, 10:00pm
The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.
April 17th 2020, 12:13am
Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.
April 15th 2020, 11:32pm
The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.
